Proactive
16 Jan 2020
NetTargets, Inc CFO Jongho Baek sat down with Proactive at the Biotech Showcase 2020 in San Francisco. The South Korea-based company is a spin out of KAIST, one of South Korea’s top research institutes, and is an early-stage drug discovery and development firm based on AI-enhanced systems biology.
Find more information on Stocktube, where the original article was published.
NetTargets will contribute its proprietary AI-based systems biology modeling technology to WOOJUNGBIO’s Open Innovation Project. By enabling quantitative simulation of biological responses and prediction of drug mechanisms, we are helping to shape a next-generation bioevaluation platform in the era of AI transformation.
NetTargets has been selected as one of the top 10 semifinalists among hundreds of drug discovery startups worldwide. The AI Discovery Award is an annual recognition by Nebius AI, a European AI-centric public cloud provider with global reach.
